Skip to Content
Morningstar
Get 14 Days Free

Vertex Pharmaceuticals Inc VRTX

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Narrow-Moat Vertex Reports Strong Q1 Results; Reiterating $259 Fair Value Estimate

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

Vertex Pharmaceuticals reported solid first-quarter results that outperformed FactSet consensus estimates on the top and bottom lines, driven by continued strong execution of its cystic fibrosis franchise. We are maintaining our narrow moat rating and $259 fair value estimate. 

Read Full Analysis

Company Profile

Business Description

Vertex Pharmaceuticals Inc discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. The company's pipeline also includes genetic therapies like CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. In addition, Vertex is focusing on developing therapies for pain, type 1 diabetes, inflammatory diseases, influenza, and other rare diseases.

Contact
50 Northern Avenue
Boston, MA, 02210
T +1 617 341-6100
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Aggressive Growth
Employees 3,400

Related

Fund Spy
Digging Into Fidelity Contrafund
We reveal how the fund’s underlying holdings stack up on 11 measures of equity-related risk.
Amy C. Arnott
Premium Article
5 Stocks With More Room to Run
Premium Exclusive: These stocks have momentum on their side yet still look undervalued by our metrics.
Susan Dziubinski
US Videos
We See This Firm Emerging as a Rare-Disease Powerhouse
Vertex Pharmaceutical's monopoly in the cystic fibrosis market forms the basis of our narrow-moat rating, and we expect that moat to continue to grow.
Kelsey Tsai
Our Picks
5 Stocks With More Room to Run
These stocks have gained twice as much as the S&P 500 in 2017 yet remain undervalued according to our metrics.
Susan Dziubinski
Stock Strategist
Vertex Is a Rare-Disease Powerhouse
The shares currently look undervalued ahead of further drug approval.
Kelsey Tsai
US Videos
Weekly Wrap: Utilities Still Have Opportunity
Trump's review of the Clean Power Plan shouldn't alter the long-term move toward natural gas and renewables. Plus, active management shakeup at BlackRock, and Vertex soars after trial.
Morningstar.com
Stock Analyst Update
Even After Rally, Vertex Undervalued
Shares soared following favorable news from the narrow-moat drugmaker's pivotal trials, yet we see further upside.
Kelsey Tsai
Stock Analyst Update
Why We're Still Bullish on Vertex Despite Low Guidance
The market is underestimating Vertex's entrenched position in the cystic fibrosis market supported by a robust pipeline of next-generation products.
Kelsey Tsai
Fund Spy
The Year in U.S. Equity Funds: Resilient in a Tumultuous 2016
In a year of unexpected events, U.S. stocks rose again with small caps outperforming for the first time since 2013.
Andrew Daniels
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Oct. 15.
Morningstar.com
Stock Analyst Update
Vertex: News Creates Opportunity in Shares
Despite a slowdown in Orkambi refills, this narrow-moat drugmaker's burgeoning cystic fibrosis portfolio should create a dominant franchise in this lucrative rare disease market.
Kelsey Tsai
Fund Times
Stock Picks from Morningstar Analysts
A trio of Morningstar analysts share their outlooks for and opportunities in the healthcare, consumer, and basic materials sectors.
Susan Dziubinski
US Videos
The Picks Panel: Best Ideas From Morningstar Analysts
Whether you need to fill a hole in your retirement portfolio or want to find a world-class company at a bargain-basement stock price, a trio of Morningstar specialists share their shopping lists of topnotch candidates.
Morningstar.com
Our Picks
Picks from Morningstar's Senior Researchers
Morningstar's Russ Kinnel, Ben Johnson, and Elizabeth Collins discuss their favorite investment ideas among mutual funds, ETFs, and stocks.
Christine Benz
US Videos
We Think This Narrow-Moat Biotech Is Cheap
With an increasingly dominant position in cystic fibrosis, Vertex’s competitive position is strong, and the stock's sell-off has been unwarranted.
Stefan Quenneville, CFA
Stock Strategist
We See Value in Vertex
A strong competitive position in the cystic fibrosis market gives the firm a narrow moat.
Stefan Quenneville, CFA
US Videos
A Good Time to Get Into Biotech
Some high-quality biotech names are trading at substantial discounts, as the market reacts to near-term concerns over pricing and biosimilar competition.
Stefan Quenneville, CFA
Market Update
Is There Opportunity in Personalized Medicine?
Although we're in the early innings of the personal-medication revolution, the stock prices of most biotech companies are sky-high.
John Waggoner
Fund Spy: Morningstar Medalist Edition
An Early Line on the Morningstar Domestic-Stock Fund Manager of the Year
These managers could be among those considered for the 2014 award.
Dan Culloton
US Videos
A Favorable Prognosis for This Pharma Stock
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Stefan Quenneville, CFA